Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?
作者信息
Suzuki Hidekazu, Mori Hideki
机构信息
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Translational Research Center for Gastrointestinal Diseases (TARGID), University of Leuven, Leuven, Belgium.
出版信息
United European Gastroenterol J. 2021 Feb;9(1):7-8. doi: 10.1177/2050640620975357. Epub 2021 Feb 12.
Abstract
摘要
相似文献
1
Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?单粒胶囊铋剂四联疗法：当下的首选，但下一步该何去何从？
United European Gastroenterol J. 2021 Feb;9(1):7-8. doi: 10.1177/2050640620975357. Epub 2021 Feb 12.
2
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.如何有效使用铋剂四联疗法：优点、缺点与问题
Gastroenterol Clin North Am. 2015 Sep;44(3):537-63. doi: 10.1016/j.gtc.2015.05.003. Epub 2015 Jun 19.
3
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.基于铋剂的幽门螺杆菌四联疗法——一种单一三联胶囊加兰索拉唑。
Aliment Pharmacol Ther. 2000 Jan;14(1):85-9. doi: 10.1046/j.1365-2036.2000.00686.x.
4
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.在标准三联疗法或不含铋剂的四联疗法失败后，采用含左氧氟沙星和铋剂的四联疗法进行幽门螺杆菌二线挽救治疗。
Aliment Pharmacol Ther. 2015 Apr;41(8):768-75. doi: 10.1111/apt.13128. Epub 2015 Feb 23.
5
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.欧洲幽门螺杆菌管理注册研究：单胶囊铋剂四联疗法在真实临床实践中有效。
United European Gastroenterol J. 2021 Feb;9(1):38-46. doi: 10.1177/2050640620972615. Epub 2021 Feb 11.
6
Practical Aspects in Choosing a Helicobacter pylori Therapy.选择幽门螺杆菌治疗方法的实际考量
Gastroenterol Clin North Am. 2015 Sep;44(3):519-35. doi: 10.1016/j.gtc.2015.05.004. Epub 2015 Jun 19.
7
[Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of ].[传统三联疗法与含铋新四联疗法在一线根除治疗中的比较] （原文句子不完整，翻译仅供参考整体结构）
Orv Hetil. 2019 Aug;160(34):1340-1345. doi: 10.1556/650.2019.31477.
8
[Acid-related diseases. What is the current rescue treatment of choice for Helicobacter pylori: quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) or triple therapy with proton pump inhibitor, amoxicillin and levofloxacin?].[酸相关性疾病。幽门螺杆菌目前的首选挽救治疗方案是什么：四联疗法（质子泵抑制剂、铋剂、四环素和甲硝唑）还是质子泵抑制剂、阿莫西林和左氧氟沙星的三联疗法？]
Gastroenterol Hepatol. 2008 Jun-Jul;31(6):400-1. doi: 10.1157/13123612.
9
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.含小檗碱的四联疗法用于初次根除幽门螺杆菌：一项开放标签的随机IV期试验。
Medicine (Baltimore). 2017 Aug;96(32):e7697. doi: 10.1097/MD.0000000000007697.
10
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.一线治疗幽门螺杆菌感染中含铋四联、14 天三联疗法的比较：一项多中心、开放标签、随机试验。
Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.
引用本文的文献
1
UEG journal's editorial team.《UEG杂志》编辑团队
United European Gastroenterol J. 2022 Dec;10(10):1041-1043. doi: 10.1002/ueg2.12340. Epub 2022 Nov 24.
本文引用的文献
1
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.欧洲幽门螺杆菌管理注册研究：单胶囊铋剂四联疗法在真实临床实践中有效。
United European Gastroenterol J. 2021 Feb;9(1):38-46. doi: 10.1177/2050640620972615. Epub 2021 Feb 11.
2
Update on quinolone-containing rescue therapies for infection.感染的含喹诺酮类药物的挽救治疗的最新进展。
World J Gastroenterol. 2020 Apr 21;26(15):1733-1744. doi: 10.3748/wjg.v26.i15.1733.
3
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line treatment: a multicentre randomised trial in Japan.七日 vonoprazan 与低剂量阿莫西林双联疗法作为一线治疗：日本多中心随机试验。
Gut. 2020 Jun;69(6):1019-1026. doi: 10.1136/gutjnl-2019-319954. Epub 2020 Jan 8.
4
Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients.大都市地区一线和二线根除治疗的现状：一项针对大量患者的多中心研究。
Therap Adv Gastroenterol. 2019 Jul 4;12:1756284819858511. doi: 10.1177/1756284819858511. eCollection 2019.
5
Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia.幽门螺杆菌中性粒细胞激活蛋白多态性决定消化不良的宿主风险。
Cell Mol Gastroenterol Hepatol. 2019;8(2):295-297.e6. doi: 10.1016/j.jcmgh.2019.05.004. Epub 2019 May 18.
6
CAPZA1 determines the risk of gastric carcinogenesis by inhibiting CagA-degraded autophagy.CAPZA1 通过抑制 CagA 降解的自噬来决定胃癌发生的风险。
Autophagy. 2019 Feb;15(2):242-258. doi: 10.1080/15548627.2018.1515530. Epub 2018 Sep 10.
7
Acquisition of double mutation in caused high resistance to sitafloxacin in after unsuccessful eradication with sitafloxacin-containing regimens.在含西他沙星的治疗方案根除失败后，[具体对象]中双突变的获得导致对西他沙星产生高度耐药性。
United European Gastroenterol J. 2018 Apr;6(3):391-397. doi: 10.1177/2050640617737215. Epub 2017 Oct 8.
8
World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.全球范围内采用 H. pylori 检测-治疗根除疗法的趋势与胃癌预防策略
J Gastroenterol. 2018 Mar;53(3):354-361. doi: 10.1007/s00535-017-1407-1. Epub 2017 Nov 14.
9
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
10
Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.在抗生素耐药性日益增加的时代，幽门螺杆菌根除疗法：提高疗效的范式转变。
Gastroenterol Res Pract. 2012;2012:757926. doi: 10.1155/2012/757926. Epub 2012 Jun 19.
Zotero 插件